Unknown

Dataset Information

0

Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types

ABSTRACT:

SUBMITTER: Panettieri Jr R 

PROVIDER: S-EPMC10960583 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Tezepelumab Targeting Thymic Stromal Lymphopoietin Enhances Steroid Sensitivity in Patients With Severe Asthma.
| S-EPMC12773678 | biostudies-literature
Unknown Dupilumab and tezepelumab in severe refractory asthma: new opportunities.
| S-EPMC9152192 | biostudies-literature
Unknown Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma.
| S-EPMC8122263 | biostudies-literature
Unknown Tezepelumab achieves improvement of severe uncontrolled asthma and rhinosinusitis: Case series
| S-EPMC11986613 | biostudies-literature
Unknown Efficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction.
| S-EPMC11587167 | biostudies-literature
Unknown Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma.
| S-EPMC10369521 | biostudies-literature
Unknown Baseline type 2 biomarker levels and response to tezepelumab in severe asthma.
| S-EPMC9306691 | biostudies-literature
Unknown Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab.
| S-EPMC8399988 | biostudies-literature
Unknown Tezepelumab Improves Small Airways Dysfunction in Severe Asthma: A 52-Week Real-World Study.
| S-EPMC12782232 | biostudies-literature
Unknown Clinical and Biological Remission With Tezepelumab: The Real-World Response in Severe Uncontrolled Asthma.
| S-EPMC12186586 | biostudies-literature